The role of targeted chemical proteomics in pharmacology

British Journal of Pharmacology

Volumn 166, Issue 2, 2012, Pages 457-475

  Sutton, Chris W ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

affinity capture; chemical proteomics; cytochrome P450; drug targets; hidden proteome; metalloproteinases; protein kinases

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; BATIMASTAT; CYCLIN DEPENDENT KINASE; CYTOCHROME P450; DASATINIB; ESTERASE; GEFITINIB; HYDROLASE; ILOMOSTAT; IMATINIB; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; NILOTINIB; ORANTINIB; PAULLONE; PHOSPHODIESTERASE; PROTEIN KINASE; PROTEINASE; PURVALANOL; ROSCOVITINE; SERINE HYDROLASE; SILDENAFIL; STAUROSPORINE; SU 66688; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; AVIDIN CHROMATOGRAPHY; BINDING AFFINITY; BIOINFORMATICS; CHROMATOGRAPHY; DATA BASE; DRUG DESIGN; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; GEL CHROMATOGRAPHY; HUMAN; INTERNET; MASS SPECTROMETRY; NONHUMAN; PHARMACOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEOMICS; REVIEW; ROBOTICS; SEARCH ENGINE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HISTONE DEACETYLASES; HUMANS; MALARIA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORIC DIESTER HYDROLASES; PROTEOMICS;

EID: 84859891445     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01778.x     Document Type: Review

References (67)

1. Aebersold R, Mann M, (2003). Mass spectrometry-based proteomics. Nature 422: 198-207. (Pubitemid 36362757)
2. Bach S, Knockaert M, Reinhardt J, Lozach O, Schmitt S, Baratte B, et al,. (2005). Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280: 31208-31219. (Pubitemid 41291858)
3. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al,. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25: 1035-1044. (Pubitemid 47517638)
4. Bauer A, Kuster B, (2003). Affinity purification-mass spectrometry. Powerful tools for the characterization of protein complexes. Eur J Biochem 270: 570-578. (Pubitemid 36286570)
5. Birner-Gruenberger R, Hermetter A, (2007). Activity-based proteomics of lipolytic enzymes. Curr Drug Discov Technol 4: 1-11. (Pubitemid 47039140)
6. Birner-Gruenberger R, Susani-Etzerodt H, Kollroser M, Rechberger GN, Hermetter A, (2008). Lipolytic and esterolytic activity-based profiling of murine liver. Proteomics 8: 3645-3656.
7. Boswell-Smith V, Spina D, Page CP, (2006). Phosphodiesterase inhibitors. Br J Pharmacol 147 (Suppl. 1): S252-S257. (Pubitemid 43077283)
8. Bregant S, Huillet C, Devel L, Dabert-Gay AS, Beau F, Thai R, et al,. (2009). Detection of matrix metalloproteinase active forms in complex proteomes: evaluation of affinity versus photoaffinity capture. J Proteome Res 8: 2484-2494.
9. Brehmer D, Godl K, Zech B, Wissing J, Daub H, (2004). Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics 3: 490-500. (Pubitemid 38714290)
10. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al,. (2005). Cellular targets of gefitinib. Cancer Res 65: 379-382.
11. Brennan JP, Miller JI, Fuller W, Wait R, Begum S, Dunn MJ, et al,. (2006). The utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. Mol Cell Proteomics 5: 215-225. (Pubitemid 43329300)
12. Dabert-Gay AS, Czarny B, Devel L, Beau F, Lajeunesse E, Bregant S, et al,. (2008). Molecular determinants of matrix metalloproteinase-12 covalent modification by a photoaffinity probe: insights into activity-based probe development and conformational variability of matrix metalloproteinases. J Biol Chem 283: 31058-31067.
13. Dadvar P, Kovanich D, Folkers GE, Rumpel K, Raijmakers R, Heck AJ, (2009a). Phosphatidylethanolamine-binding proteins, including RKIP, exhibit affinity for phosphodiesterase-5 inhibitors. Chembiochem 10: 2654-2662.
14. Dadvar P, O'Flaherty M, Scholten A, Rumpel K, Heck AJ, (2009b). A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124. Mol Biosyst 5: 472-482.
15. Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, et al,. (2008). Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31: 438-448.
16. David A, Steer D, Bregant S, Devel L, Makaritis A, Beau F, et al,. (2007). Cross-linking yield variation of a potent matrix metalloproteinase photoaffinity probe and consequences for functional proteomics. Angew Chem Int Ed Engl 46: 3275-3277. (Pubitemid 46973476)
17. Edwards A, (2009). Large-scale structural biology of the human proteome. Annu Rev Biochem 78: 541-568.
18. Fischer JJ, Graebner Baessler OY, Dalhoff C, Michaelis S, Schrey AK, et al,. (2010). Comprehensive identification of staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass Spectrometry (CCMS). J Proteome Res 9: 806-817.
19. Fischer JJ, Michaelis S, Schrey AK, Diehl A, Graebner OY, Ungewiss J, et al,. (2011). SAHA Capture Compound-A novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders. Proteomics 11: 1-9.
20. Freije JR, Klein T, Ooms JA, Franke JP, Bischoff R, (2006). Activity-based matrix metallo-protease enrichment using automated, inhibitor affinity extractions. J Proteome Res 5: 1186-1194. (Pubitemid 43727797)
21. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al,. (2007). Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404: 15-21. (Pubitemid 46788080)
22. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, et al,. (2003). An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 100: 15434-15439. (Pubitemid 38021007)
23. Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, et al,. (2005). Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 65: 6919-6926. (Pubitemid 41060731)
24. Goekjian PG, Jirousek MR, (1999). Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr Med Chem 6: 877-903. (Pubitemid 29422200)
25. Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, Coley AM, et al,. (2002). Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 62: 1364-1372. (Pubitemid 35403831)
26. Greenbaum D, Medzihradszky KF, Burlingame A, Bogyo M, (2000). Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 7: 569-581.
27. Hesek D, Toth M, Meroueh SO, Brown S, Zhao H, Sakr W, et al,. (2006). Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol 13: 379-386.
28. Ingelman-Sundberg M, (2002). Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 181-182: 447-452. (Pubitemid 36015735)
29. Kidd D, Liu Y, Cravatt BF, (2001). Profiling serine hydrolase activities in complex proteomes. Biochemistry 40: 4005-4015. (Pubitemid 32280438)
30. Knockaert M, Meijer L, (2002). Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem Pharmacol 64: 819-825. (Pubitemid 35232255)
31. Knockaert M, Gray N, Damiens E, Chang YT, Grellier P, Grant K, et al,. (2000). Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol 7: 411-422. (Pubitemid 30400044)
32. Knockaert M, Wieking K, Schmitt S, Leost M, Grant KM, Mottram JC, et al,. (2002). Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. J Biol Chem 277: 25493-25501. (Pubitemid 34951864)
33. Kok K, Geering B, Vanhaesebroeck B, (2009). Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 34: 115-127.
34. Kruse U, Pallasch CP, Bantscheff M, Eberhard D, Frenzel L, Ghidelli S, et al,. (2011). Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25: 89-100.
35. Lange V, Picotti P, Domon B, Aebersold R, (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4: 222.
36. Lee WC, Lee KH, (2004). Applications of affinity chromatography in proteomics. Anal Biochem 324: 1-10. (Pubitemid 37491116)
37. Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, et al,. (2007). Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A 104: 4389-4394. (Pubitemid 47186236)
38. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al,. (2010). A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6: 291-299.
39. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al,. (1999). Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17: 676-682. (Pubitemid 29316146)
40. Liu Y, Patricelli MP, Cravatt BF, (1999). Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci U S A 96: 14694-14699. (Pubitemid 30019702)
41. Lolli G, Thaler F, Valsasina B, Roletto F, Knapp S, Uggeri M, et al,. (2003). Inhibitor affinity chromatography: profiling the specific reactivity of the proteome with immobilized molecules. Proteomics 3: 1287-1298. (Pubitemid 36929550)
42. MacKinnon AL, Garrison JL, Hegde RS, Taunton J, (2007). Photo-leucine incorporation reveals the target of a cyclodepsipeptide inhibitor of cotranslational translocation. J Am Chem Soc 129: 14560-14561. (Pubitemid 350207861)
43. Murphy G, Nagase H, (2008). Progress in matrix metalloproteinase research. Mol Aspects Med 29: 290-308.
44. Nebert DW, Russell DW, (2002). Clinical importance of the cytochromes P450. Lancet 360: 1155-1162. (Pubitemid 35246494)
45. Ong SE, Mann M, (2005). Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1: 252-262.
46. Oppermann FS, Gnad F, Olsen JV, Hornberger R, Greff Z, Keri G, et al,. (2009). Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8: 1751-1764.
47. Pasquali C, Bertschy-Meier D, Chabert C, Curchod ML, Arod C, Booth R, et al,. (2007). A chemical proteomics approach to phosphatidylinositol 3-kinase signaling in macrophages. Mol Cell Proteomics 6: 1829-1841. (Pubitemid 350201863)
48. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al,. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110: 4055-4063. (Pubitemid 350248462)
49. Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, et al,. (2011). A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 24: 44-50.
50. Saghatelian A, Jessani N, Joseph A, Humphrey M, Cravatt BF, (2004). Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A 101: 10000-10005. (Pubitemid 38891185)
51. Saxena C, Zhen E, Higgs RE, Hale JE, (2008). An immuno-chemo-proteomics method for drug target deconvolution. J Proteome Res 7: 3490-3497.
52. Saxena C, Bonacci TM, Huss KL, Bloem LJ, Higgs RE, Hale JE, (2009). Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool. J Proteome Res 8: 3951-3957.
53. Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, et al,. (2005). Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 280: 41439-41448. (Pubitemid 41832203)
54. Shiyama T, Furuya M, Yamazaki A, Terada T, Tanaka A, (2004). Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg Med Chem 12: 2831-2841. (Pubitemid 38622119)
55. Sieber SA, Niessen S, Hoover HS, Cravatt BF, (2006). Proteomic profiling of metalloprotease activities with cocktails of active-site probes. Nat Chem Biol 2: 274-281.
56. Speers AE, Adam GC, Cravatt BF, (2003). Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc 125: 4686-4687. (Pubitemid 36505343)
57. Takahashi T, Shiyama T, Hosoya K, Tanaka A, (2006). Development of chemically stable solid phases for the target isolation with reduced nonspecific binding proteins. Bioorg Med Chem Lett 16: 447-450. (Pubitemid 41683097)
58. Trinkle-Mulcahy L, Boulon S, Lam YW, Urcia R, Boisvert FM, Vandermoere F, et al,. (2008). Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes. J Cell Biol 183: 223-239.
59. Tsugita A, (1987). Developments in protein microsequencing. Adv Biophys 23: 81-113.
60. Wan J, Roth AF, Bailey AO, Davis NG, (2007). Palmitoylated proteins: purification and identification. Nat Protoc 2: 1573-1584. (Pubitemid 47033750)
61. Wissing J, Godl K, Brehmer D, Blencke S, Weber M, Habenberger P, et al,. (2004). Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Mol Cell Proteomics 3: 1181-1193.
62. Wissing J, Jansch L, Nimtz M, Dieterich G, Hornberger R, Keri G, et al,. (2007). Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6: 537-547. (Pubitemid 46554547)
63. Wright AT, Cravatt BF, (2007). Chemical proteomic probes for profiling cytochrome p450 activities and drug interactions in vivo. Chem Biol 14: 1043-1051. (Pubitemid 47404904)
64. Wright AT, Song JD, Cravatt BF, (2009). A suite of activity-based probes for human cytochrome P450 enzymes. J Am Chem Soc 131: 10692-10700.
65. Wulff JE, Siegrist R, Myers AG, (2007). The natural product avrainvillamide binds to the oncoprotein nucleophosmin. J Am Chem Soc 129: 14444-14451. (Pubitemid 350171471)
66. Yamamoto K, Yamazaki A, Takeuchi M, Tanaka A, (2006). A versatile method of identifying specific binding proteins on affinity resins. Anal Biochem 352: 15-23.
67. Zhang Q, Major MB, Takanashi S, Camp ND, Nishiya N, Peters EC, et al,. (2007). Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc Natl Acad Sci U S A 104: 7444-7448. (Pubitemid 47185925)